Skip to content

Impact of the CT Scan in Patients With Suspected Covid-19

Diagnostic Performance and Predictive Impact of the CT Scan in Patients With Suspected Covid-19

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05079191
Acronym
SCAN-COV-HUS
Enrollment
2000
Registered
2021-10-15
Start date
2020-06-01
Completion date
2021-11-30
Last updated
2021-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Keywords

COVID-19, SARS-COV-2, Chest scanner, CT scan, RT-PCR

Brief summary

The diagnostic performance of the scanner in the indication of suspected Covid-19 is not yet well known, especially in comparison with the results of RT-PCR. The potential use of the scanner as a tool for quantifying the severity of Covid-19 disease is not yet well established, especially the variations between readers or between measurement techniques. The impact of the scanner in predicting the fate of patients with confirmed Covid-19 is not yet known.

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Adult patient (≥18 years old) * Patient admitted to Strasbourg University Hospitals for suspicion of Covid-19, between 03/01/2020 and 04/29/2020 * Availability of at least one chest CT scan during hospitalization * Subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research. Non-inclusion criteria * Patient who expressed his opposition to participating in the study * Patient under legal protection * Patient under guardianship or guardianship

Design outcomes

Primary

MeasureTime frame
Retrospective study of the chest scanner in suspected Covid-19Files analysed retrospectively from March 01, 2020 to April 29, 2020 will be examined]

Countries

France

Contacts

Primary ContactMickaël OHANA, MD, PhD
mickael.ohana@chru-strasbourg.fr33 3 69 55 11 17
Backup ContactSaïd CHAYER, PhD, HDR
said.chayer@chru-strasbourg.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026